🔥The 5 BIGGEST breakthroughs of 2023 in Alzheimer’s and dementia. 🚀 From the FDA's full approval of Leqembi, a game-changing Alzheimer's drug, to the revolutionary potential of PET scans in diagnosing Alzheimer's, get ready for groundbreaking news in #Alzheimer's and #dementia research💡 But that's not all—get ready to learn about direct-to-consumer blood tests, cutting-edge AI technology, and the latest insights on genetic testing. 🩺🔬 Don't miss this exciting discussion that's shaping the future of Alzheimer's care and prevention. Tune in now and become a part of the movement! Stay tuned by following us here and watching for updates at beingpatient.com If you loved watching this Live Talk, visit our website to find more of our Alzheimer’s coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter: https://twitter.com/Being_Patient_ Instagram: https://www.instagram.com/beingpatientvoices/ Facebook: https://www.facebook.com/beingpatientalzheimers LinkedIn: https://www.linkedin.com/company/being-patient Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/ #AlzheimersBreakthroughs #DementiaResearch #Leqembi #PETScans #BloodTests #AItechnology #GeneticTesting #BeingPatient

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related